Related Experiment Video
Updated: May 28, 2025

Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
Automated Insulin Delivery in Adults With Type 2 Diabetes: A Nonrandomized Clinical Trial
Francisco J Pasquel1, Georgia M Davis1, David M Huffman2
1Emory University School of Medicine, Atlanta, Georgia.
Automated insulin delivery (AID) significantly lowered hemoglobin A1c (HbA1c) in adults with type 2 diabetes. This study suggests AID is a safe and effective option for insulin-treated type 2 diabetes management.
Area of Science:
- Endocrinology
- Metabolic Diseases
- Medical Devices
Background:
- Limited data exists on automated insulin delivery (AID) systems for type 2 diabetes.
- Additional treatment options are needed for type 2 diabetes patients on insulin therapy.
Purpose of the Study:
- To evaluate the association between AID use and hemoglobin A1c (HbA1c) levels in a diverse adult population with type 2 diabetes.
- To assess the safety and efficacy of AID systems in this patient group.
Main Methods:
- A single-arm prospective trial involving 305 adults with type 2 diabetes using insulin.
- Participants used the Omnipod 5 AID system for 13 weeks after a 14-day standard therapy phase.
- The primary outcome was the change in HbA1c levels at 13 weeks compared to baseline.
Main Results:
- HbA1c levels decreased from 8.2% at baseline to 7.4% after 13 weeks of AID use (mean difference -0.8%).
- Time in target glucose range (70-180 mg/dL) increased significantly from 45% to 66%.
- Hypoglycemia rates were noninferior to standard therapy, with one severe hypoglycemia event reported.
Conclusions:
- Automated insulin delivery (AID) demonstrated a significant reduction in HbA1c levels in adults with type 2 diabetes.
- AID appears to be a beneficial and safe treatment option for individuals with type 2 diabetes requiring insulin therapy.
- The findings support the expanded use of AID systems in managing type 2 diabetes.
More Related Videos
06:13Author Spotlight: Exploring the Impact of Reduced Resistance Exercise Volume on Metabolic Health
Published on: December 1, 2023
00:04A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
Published on: September 20, 2019
Related Concept Videos
Insulin: Dosing Regimen and Adverse Effects
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Insulin Formulations: Types and Delivery
Short-acting insulins are divided into...
Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Diabetes Mellitus: Type 2 and Gestational
Diabetes: Symptoms, Diagnosis, and Complications